Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.

• Exbumin Provides Improved Performance and Stability in Vaccine Development
• Formulation and Production of Serum-Free OptiVERO Media
• Revolutionizing T Cell Immunotherapies
• Recent Advances of Chemical Definition of Cell Culture Media and Excipients for Virus and Viral Vector Manufacturing
• OptiPEAK T-Lymphocyte Application Note
• Poster 2021: Application of Biomass Probe with Chemically Defined Media in iCELLis
• Poster 2021: Lentiviral Vector Production in a Chemically Defined, Blood-Free and Serum-Free Medium
• Emergence of a Blood-Free rHSA
• 2021 Product Catalog
• Enhancement of Transient Transfection with Serum-Free and Blood-Free Transferrin
• Accelerating Vaccine Development Through Use of Blood-Free Components
• Cell Culture Media & The Emergence of Blood-Free Components
• OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media
• OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note
• OptiVERO – Guidelines for Use
• rHSA Reconstitution Video Protocol
• 2020 Product Catalog
• OptiPEAK HEK293t – Expansion of Adherent HEK293t Cells in Flasks in Chemically Defined Cell Culture Media Application Note
• OptiPEAK HEK 293t – InVitria/Pall Biotech iCELLis Poster
• OptiPEAK HEK293t – Product Specifications
• OptiPEAK HEK293t – Safety Data Sheet
• Optibumin – Safety Data Sheet
• Lysosure – Safety Data Sheet
• Lysobac – Safety Data Sheet
• Lysobac – Brochure – E.Coli Lysis
• Lysobac – Guidelines for Use
• ITSE+A – Guidelines for Use
• ITSE+A – Specifications
• ITSE AF – Safety Data Sheet
• ITSE AF – Guidelines for Use
• ITSE+A – Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture Application Note
• ITSE AF – Brochure
• ITS – Guidelines for Use
• ITS – Specifications
• Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note
• Exbumin – Safety Data Sheet
• Exbumin – Guidelines for Use
• Optiferrin – Product Brochure
• Optiferrin – Using rTransferrin in the Expansion of Hematopoietic Stem Cells Application Note
• Optiferrin – Guidelines for Use
• Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes
• Cellastim S – Safety Data Sheet
• Cellastim S – Product Specifications
• Cellastim S – Reconstitution Application Note
• Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin (Cellastim™)
• ITSE Animal-Free Brochure
• Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease
• InVitria: Solving the Vaccine Supply Challenge
• Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times
• Expansion of Adherent HEK293t Cells in Flasks in Chemically Defined Cell Culture Media
• SARS-CoV2 and Influenza: A Double Threat
• High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media
• Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease
• Expansion of Adherent HEK293t Cells in Flasks in Chemically Defined Cell Culture Media
• Stabilizing Virus with Albumin to Improve Yield
• Controlling Impurities in Cell Culture Media
• Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells
• Reconstitution of Cellastim S for Cell-Culture Applications
• BioInnovation on Parade: Philly Stands Proud for BIO 2019!
• Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells
• T Regulatory Cells, The Next T Cell Frontier?
• Exploring the Latest Research and Opportunities in T-reg Therapy
• Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
• ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy
• Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines
• Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media
• Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media
• Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture
• Expansion of VERO Cells Without Serum in Chemically Defined Cell Culture Media
• Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial
• Expansion of T Cells without Serum in Chemically Defined Media
• ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy
• Phacilitate 2019 and World Stem Cell Summit
• Join InVitria at ECI 2019
• Join InVitria at Phacilitate 2019
• Cellastim S – Guidelines for Use
• Happy Holidays from the InVitria Team!
• BIO Europe 2018: From Lab Innovations to Commercial Realities
• WEBINAR: The Cell Culture Revolution: Commercializing Therapeutic Cell Systems
• InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area
• BIO 2018: The Emergence of Gene & Cell Therapy
• InVitria at the American Association of Immunologists 2018 Conference
• Transferrin: An Iron Transport Protein – Recombinant Human Transferrin in Cell Culture Media
• InVitria’s Top Insights from ISCT 2018 – Montreal
• 3 Takeaways from the World Vaccine Congress 2018